Rubens Moreno de Freitas1, Rubens Spin-Neto, Elcio Marcantonio Junior, Luís Antônio Violin Dias Pereira, Ulf M E Wikesjö, Cristiano Susin. 1. Department of Oral Diagnosis and Surgery - Periodontics, UNESP - Universidade Estadual Paulista, Araraquara Dental School, Araraquara, SP, Brazil; Laboratory for Applied Periodontal & Craniofacial Regeneration, Department of Periodontics and Oral Biology, College of Dental Medicine, Department of Orthopedic Surgery, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA.
Abstract
PURPOSE: The aim of this systematic review was to evaluate clinical and safety data for recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier when used for alveolar ridge/maxillary sinus augmentation in humans. MATERIALS AND METHODS: Clinical studies/case series published 1980 through June 2012 using rhBMP-2/ACS were searched. Studies meeting the following criteria were considered eligible for inclusion: >10 subjects at baseline and maxillary sinus or alveolar ridge augmentation not concomitant with implant placement. RESULTS: Seven of 69 publications were eligible for review. rhBMP-2/ACS yielded clinically meaningful bone formation for maxillary sinus augmentation that would allow placement of regular dental implants without consistent differences between rhBMP-2 concentrations. Nevertheless, the statistical analysis showed that sinus augmentation following autogenous bone graft was significantly greater (mean bone height: 1.6 mm, 95% CI: 0.5-2.7 mm) than for rhBMP-2/ACS (rhBMP-2 at 1.5 mg/mL). In extraction sockets, rhBMP-2/ACS maintained alveolar ridge height while enhancing alveolar ridge width. Safety reports did not represent concerns for the proposed indications. CONCLUSIONS: rhBMP-2/ACS appears a promising alternative to autogenous bone grafts for alveolar ridge/maxillary sinus augmentation; dose and carrier optimization may expand its efficacy, use, and clinical application.
PURPOSE: The aim of this systematic review was to evaluate clinical and safety data for recombinant humanbone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier when used for alveolar ridge/maxillary sinus augmentation in humans. MATERIALS AND METHODS: Clinical studies/case series published 1980 through June 2012 using rhBMP-2/ACS were searched. Studies meeting the following criteria were considered eligible for inclusion: >10 subjects at baseline and maxillary sinus or alveolar ridge augmentation not concomitant with implant placement. RESULTS: Seven of 69 publications were eligible for review. rhBMP-2/ACS yielded clinically meaningful bone formation for maxillary sinus augmentation that would allow placement of regular dental implants without consistent differences between rhBMP-2 concentrations. Nevertheless, the statistical analysis showed that sinus augmentation following autogenous bone graft was significantly greater (mean bone height: 1.6 mm, 95% CI: 0.5-2.7 mm) than for rhBMP-2/ACS (rhBMP-2 at 1.5 mg/mL). In extraction sockets, rhBMP-2/ACS maintained alveolar ridge height while enhancing alveolar ridge width. Safety reports did not represent concerns for the proposed indications. CONCLUSIONS:rhBMP-2/ACS appears a promising alternative to autogenous bone grafts for alveolar ridge/maxillary sinus augmentation; dose and carrier optimization may expand its efficacy, use, and clinical application.
Authors: Sophia P Pilipchuk; Alexandra B Plonka; Alberto Monje; Andrei D Taut; Alejandro Lanis; Benjamin Kang; William V Giannobile Journal: Dent Mater Date: 2015-02-18 Impact factor: 5.304
Authors: Anne D Talley; Kerem N Kalpakci; Daniel A Shimko; Katarzyna J Zienkiewicz; David L Cochran; Scott A Guelcher Journal: Tissue Eng Part A Date: 2016-03-14 Impact factor: 3.845